Navigation Links
Genomic Health Announces Formation of New Genetics Subsidiary
Date:2/6/2012

er test, the first multigame expression test developed for the assessment of risk of recurrence in patients with stage II disease.  As of December 31, 2011, more than 10,000 physicians in over 65 countries had ordered more than 265,000 Oncotype DX tests.  Genomic Health has a robust pipeline focused on developing tests to optimize the treatment of prostate and renal cell cancers, as well as additional treatment decisions in breast and colon cancers.  The company is based in Redwood City, California with European headquarters in Geneva, Switzerland.  For more information, please visit, www.GenomicHealth.com.  To learn more about Oncotype DX tests, visit: www.OncotypeDX.com and www.mybreastcancertreatment.org

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's plans to establish and invest in a subsidiary focused on clinical and commercial  applications of genetics; our expectations regarding the potential for clinical and commercial applications of genetic information; our plans to make genomic services available in 2013; our expectations regarding the subsidiary's future contributions to our long term profit expectations; our expectations regarding the cost of DNA sequencing; our belief regarding our ability to leverage our global infrastructure in cancer to integrate the human genome more broadly into medical practice; our 2012 financial guidance; the focus and attributes of the company's product pipeline; the ability of the company to develop additional tests in the future; and the ability of any potential tests the company may develop to optimize cancer treatment.  Forward-looking statements are subject to ris
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Personalized Medicine - The Genomic Revolution in Cardiac Care
4. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
5. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
6. Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions
7. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
8. Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium
9. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
10. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
11. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 28, 2015 Research ... addition of the "Investigation Report on China,s ... Developed by AstraZeneca plc, quetiapine (under ... drug for the treatment of schizophrenia. Approved by ... listed in the Catalogue of Drugs for the ...
(Date:8/28/2015)... 28, 2015 Research and ... the "Investigation Report on China,s Ranibizumab Market, 2012-2019" ... Novartis, ranibizumab was approved by CFDA to treat wet ... Lucentis, a product of Novartis, is available in the ... self- developed drug for the treatment of wet AMD ...
(Date:8/28/2015)... Perrigo Company plc ("Perrigo") (NYSE: PRGO ... (NASDAQ: MYL ) shareholder vote regarding its planned ... of Mylan,s offer to Perrigo shareholders have always been, ... careful reflection of the value available to Perrigo shareholders, ... Mylan has allowed its shareholders to consider," said ...
Breaking Medicine Technology:China Quetiapine Market Investigation Report 2010-2019 2Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5
... SAN MARINO, Calif. , July 6 ... of targeted genetic medicine, received a notice of allowance ... leading tumor-targeted gene delivery platform. The issuance of this ... follows on the heels of two major patent issuances ...
... N.J. , July 6 Nephros, Inc. (OTC Bulletin ... for therapeutic applications, infection control, and water purification, today reported that ... a standard component of its MRO portable reverse osmosis water treatment ... , ...
Cached Medicine Technology:Small, Smart, Stealth Nanoparticles Seek-and-Destroy Metastatic Cancers, as Epeius Biotechnologies Advances its Intellectual Property Estate With Additional U.S. Patents 2Small, Smart, Stealth Nanoparticles Seek-and-Destroy Metastatic Cancers, as Epeius Biotechnologies Advances its Intellectual Property Estate With Additional U.S. Patents 3Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems 2Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems 3Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems 4Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems 5
(Date:8/30/2015)... Auckland, NZ (PRWEB) , ... August 30, 2015 ... ... enterprise collaboration across platforms and devices, today announced it is a Silver Sponsor ... 1, 2015 at Sky City Convention Centre in Auckland, NZ. Throughout the event, ...
(Date:8/30/2015)... Raton, Fl (PRWEB) , ... August 30, 2015 , ... ... InHealth Media. Nutritional Products International and InHealth media is a global sales and ... , “We are extremely pleased to continue our business relationship with Mr. Reid Eckert, ...
(Date:8/29/2015)... ... August 30, 2015 , ... On September 30, 2015, the ... of the 10 regionally accredited Maricopa Community Colleges , will be hosting a ... students pursuing employment information and opportunities. , The Expo has expanded to much more ...
(Date:8/29/2015)... ... August 29, 2015 , ... Targeted therapies, made possible by ... of patients, according to a newly published report. Surviving Mesothelioma has more on ... , The authors of the new paper focus on several types of ...
(Date:8/29/2015)... , ... August 29, 2015 , ... ... angina, chronic obstructive pulmonary disease (including emphysema), or asthma, are at higher risk ... angina, previous heart attack, heart failure or heart-rhythm problems (arrhythmia or irregular heartbeat) ...
Breaking Medicine News(10 mins):Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 2Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 3Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 4Health News:Nutrition Guru Continues Relationship With Renowned Health and Wellness Company 2Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2
... issue of Technology & Innovation, Proceedings of the ... bright future and enormous need for stem cell therapeutics ... and deadly diseases. http://www.ingentaconnect.com/content/cog/ti/2011/00000013/00000001 ... cell replacement" procedures to restructure damaged organs, tissues and ...
... ICU , Intensive care units are facing staffing ... A recent study, conducted by physicians from Beth Israel ... York, NY, studying 590 daytime admissions in two intensive ... address these staff shortages. In the study, no ...
... 8 to 18 consume an average of 13 hours of ... their white counterparts, according to a Northwestern University report, the ... by race and ethnicity. "In the past decade, the ... doubled for blacks and quadrupled for Hispanics," says Northwestern Professor ...
... researcher in the University of Cincinnati (UC) Department of ... from the Emergency Medicine Foundation to study the implementation ... (ED). The award will support the work of ... of Medicine. Ward has spent the past year focusing ...
... This release is available in French . Montreal, ... needs to be decriminalized, according to a new report published in ... and University of Windsor researchers, the study calls for sweeping changes ... "We must not only change our laws, we must also revamp ...
... Houston environmental engineer will test parts of Galveston Bay ... officials determine the best way to handle those pollutants., ... through a Texas Commission on Environmental Quality (TCEQ) grant ... last fall for similar research in the Houston Ship ...
Cached Medicine News:Health News:The future of stem cell applications challenging, bright 2Health News:Chest journal news briefs -- June 2011 issue 2Health News:Study: Stark differences in media use between minority and white youth 2Health News:Study: Stark differences in media use between minority and white youth 3Health News:Study: Stark differences in media use between minority and white youth 4Health News:Using simulation to model the implementation of electronic health records 2Health News:Dangerous and under the radar 2Health News:Dangerous and under the radar 3Health News:University of Houston researcher receives grant to study water pollutants 2
... anyone using the Farnsworth D15, L'Anthony desaturated test ... patients cannot avoid touching the color disks with ... Further, the disks are very easy to loose.,We ... in order to solve these problems. We have ...
... Farnsworth Dichotomous testing sets are designed ... The Farnsworth D15 test is used to ... Normal. The L'Anthony Desaturated test is much ... mild deficiency from Normal. Both of ...
... The NOW Strep A test is as easy ... minutes to results. Increase patient satisfaction with rapid ... can treat your patient immediately with the appropriate ... , ,Intended Use: ,The NOW® Strep A Test ...
12 mm single use, reloadable laparoscopic linear stapler with titanium staples....
Medicine Products: